The IPO window for biotech companies is open, but strong firms may still opt for M&A with Big Pharma. Investors are selective, favoring 'best in class' assets. Deal values are increasing, with China emerging as a key player.
The biotech IPO market is showing signs of recovery, but top dealmakers at JPMorgan suggest strong companies may still opt for acquisition by Big Pharma. Investors are more selective, leading many biotechs to pursue dual-track strategies. This trend reflects a broader healthcare dealmaking rebound driven by Big Pharma's need to replenish pipelines.
The biotech IPO market is showing signs of life, but top dealmakers at JPMorgan suggest that strong companies are still more likely to be acquired by Big Pharma. Investors are more selective, leading many biotechs to pursue dual-track strategies.
